TAK-755 (Takeda Pharmaceutical Co. Ltd.) is an investigational, intravenous recombinant ADAMTS13 enzyme replacement therapy proposed for treatment of congenital thrombotic thrombocytopenic purpura.
If you have a Hayes login, click here to view the full report on the Knowledge Center.